• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Relay Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates

    2/26/25 4:05:00 PM ET
    $RLAY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $RLAY alert in real time by email

     Initiation of Phase 3 ReDiscover-2 trial of RLY-2608 + fulvestrant anticipated in the middle of 2025 in PI3Kα-mutated, CDK4/6 pre-treated, HR+/HER2- metastatic breast cancer

    Presented interim data for RLY-2608 + fulvestrant showing 11.4-month median PFS in 2L patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer

    Continued progression of other front-line breast cancer regimens, including initiation of atirmociclib triplet, and planning for development of future oral endocrine therapy combinations underway

    Approximately $780 million in cash, cash equivalents and investments at end of Q4 2024, which will be prioritized to fully fund the execution of the ReDiscover-2 Phase 3 trial

    CAMBRIDGE, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today reported fourth quarter and full year 2024 financial results and corporate highlights.

    "Our RLY-2608 breast cancer program continued to advance and develop rapidly in 2024, driven by positive maturation of the RLY-2608 + fulvestrant doublet dataset, now with over 100 patients dosed and median PFS of 11.4 months in second-line patients. We also continue to make progress with our investigational triplet combinations, which we believe could potentially allow RLY-2608 to address patients in earlier settings," said Sanjiv Patel, M.D., President and Chief Executive Officer of Relay Therapeutics. "Looking forward into 2025, it is our top priority to continue advancing our clinical programs, including the initiation of the RLY-2608 + fulvestrant Phase 3 trial in breast cancer patients. With a strong capital position that supports the execution of that pivotal trial, and a team with proven development experience, I am confident in our abilities to meaningfully advance these programs towards patients in oncology and genetic disease areas."

    Initiation of ReDiscover-2 Phase 3 trial of RLY-2608 + Fulvestrant in the Middle of 2025

    • Relay Tx has conducted an end of Phase 2 meeting with the Food and Drug Administration (FDA) and announces the Phase 3 trial design, dose, and plans to initiate the trial in mid-2025
    • Design
      • Planned Phase 3 registrational study (ReDiscover-2) is a randomized, open-label, multicenter clinical trial that will evaluate the safety and efficacy of RLY-2608 + fulvestrant in PI3Kα-mutated, HR+/HER2- advanced breast cancer patients previously treated with a CDK4/6 inhibitor
      • Comparator arm will be capivasertib + fulvestrant
      • Key inclusion criteria include:
        • Patients must be CDK4/6-experienced (either in the adjuvant or metastatic setting)
        • Patients must have been on frontline endocrine therapy containing regimen for >6 months
        • Patients may have seen up to 1 prior chemotherapy and no ADC in the metastatic setting
        • Metabolic inclusion criteria: HbA1c <7% and fasting plasma glucose <140 mg/dL at baseline
      • Target enrollment is 540 patients
      • The primary endpoint is progression free survival (PFS), per RECIST 1.1 criteria, tested hierarchically in patients with PI3Kα mutations in the kinase domain only and in patients with any PI3Kα mutation (kinase + non-kinase mutations)
      • Overall survival is a key secondary endpoint with overall response rate (ORR), duration of response and quality of life as additional secondary endpoints
    • Dose
      • Phase 3 dose of RLY-2608 is 400mg twice daily (BID) in the fed state (fed)
      • A positive food effect has been observed when RLY-2608 was administered to patients in the fed state, which increased the exposure level of RLY-2608 compared to the fasted state (fasted)
      • The RLY-2608 400mg BID fed dose has been shown to achieve exposures equivalent to 600mg BID fasted in cancer patients
        • 600mg BID fasted was the dose used in our expansion cohorts

    Additional Corporate Highlights

    • RLY-2608:
      • RLY-2608 doublet: Presented interim clinical data from the open-label Phase 1b study for RLY-2608 + fulvestrant at the San Antonio Breast Cancer Symposium (SABCS) 2024, showing:
        • 11.4-month median PFS in second line (2L) patients with PI3Kα-mutated, HR+/HER2- locally advanced or metastatic breast cancer
        • 39% confirmed ORR across patients with measurable disease (n= 31)
        • 67% Clinical Benefit Rate (CBR) across all evaluable patients (32 of 48 CBR-evaluable patients; CBR defined as the proportion of patients with complete response, partial response or stable disease for at least 24 weeks)
        • Safety profile (n= 118) remained differentiated with mostly low-grade treatment- related adverse events
      • RLY-2608 triplet: Continued to advance two potential front-line triplet regimens in patients with PI3Kα- mutated, HR+, HER2- metastatic breast cancer who had previously received at least one prior CDK4/6 inhibitor, including:
        • Initiation of triplet cohort for RLY-2608 + fulvestrant + atirmociclib (Pfizer's selective CDK4 inhibitor) combination
        • Continued advancement of the ongoing RLY-2608 + fulvestrant + ribociclib combination cohort
      • Planning underway for development of next-generation endocrine therapy combinations with RLY-2608
    • Lirafugratinib:
      • Entered exclusive global licensing agreement, granting Elevar Therapeutics worldwide rights to develop and commercialize lirafugratinib
    • NRAS program:
      • Nominated development candidate, RLY-8161
    • Research:
      • Continued to consolidate and focus the research platform and portfolio on a small number of high-value targets

    Anticipated 2025 Milestones

    • RLY-2608 in Breast Cancer:
      • Initiation of Phase 3 trial in the middle of 2025
      • Additional Phase 1b doublet data in 2025
    • Vascular malformations: RLY-2608 clinical trial initiation in the first quarter of 2025
    • NRAS and Fabry programs continue to advance towards IND and timing of clinical start for each program will be phased to optimize resources to ensure the execution of the ReDiscover-2 Phase 3 trial

    Fourth Quarter and Full Year 2024 Financial Results

    Cash, Cash Equivalents and Investments: As of December 31, 2024, cash, cash equivalents, and investments totaled $781.3 million compared to approximately $750.1 million as of December 31, 2023. The company expects its current cash, cash equivalents and investments will be sufficient to fund its current operating plan into the second half of 2027.

    Revenue: There was no revenue for the fourth quarters of 2024 and 2023. Revenue was $10.0 million for the full year 2024, as compared to $25.5 million for the full year 2023. The decrease was primarily due to the timing of milestones achieved, as well as revenue recognized thereon, under the company's Collaboration and License Agreement with Genentech, Inc.

    R&D Expenses: Research and development expenses were $68.1 million for the fourth quarter of 2024, as compared to $77.5 million for the fourth quarter of 2023. Research and development expenses were $319.1 million for the full year 2024, as compared to $330.0 million for the full year 2023. The decreases were primarily due to the impact of prioritization of certain programs in the company's pipeline, as previously disclosed.

    G&A Expenses: General and administrative expenses were $16.9 million for the fourth quarter of 2024, as compared to $16.8 million for the fourth quarter of 2023. General and administrative expenses were $76.6 million for the full year 2024, as compared to $75.0 million for the full year 2023.

    Net Loss: Net loss was $76.0 million for the fourth quarter of 2024, or a net loss per share of $0.45, as compared to a net loss of $83.5 million for the fourth quarter of 2023, or a net loss per share of $0.67. Net loss was $337.7 million for the full year 2024, or a net loss per share of $2.36, as compared to a net loss of $342.0 million for the full year 2023, or a net loss per share of $2.79.

    About Relay Therapeutics

    Relay Therapeutics (NASDAQ:RLAY) is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. As the first of a new breed of biotech created at the intersection of complementary techniques and technologies, Relay Therapeutics aims to push the boundaries of what's possible in drug discovery. Its Dynamo® platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. Relay Therapeutics' initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. For more information, please visit www.relaytx.com or follow us on Twitter.

    Cautionary Note Regarding Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements regarding Relay Therapeutics' strategy, business plans and focus; the progress and timing of the clinical development of the programs across Relay Therapeutics' portfolio, including the expected timing of data readout and other clinical and developmental milestones; the expected therapeutic benefits and potential efficacy and tolerability of RLY-2608, both as a monotherapy and in combination with other agents, and its other programs, as well as the clinical data for RLY-2608; the interactions with regulatory authorities and any related approvals; the potential market opportunity for RLY-2608; the cash runway projection and the expectations regarding Relay Therapeutics' use of capital and expenses. The words "may," "might," "will," "could," "would," "should," "plan," "anticipate," "intend," "believe," "expect," "estimate," "seek," "predict," "future," "project," "potential," "continue," "target" and similar words or expressions, or the negative thereof, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

    Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks associated with: the impact of global economic uncertainty, geopolitical instability and conflicts, or public health epidemics or outbreaks of an infectious disease on countries or regions in which Relay Therapeutics has operations or does business; significant political, trade, or regulatory developments beyond Relay Therapeutics' control; the timing and anticipated results of its clinical trials, strategy, future operations and profitability; the delay or pause of any current or planned clinical trials or the development of Relay Therapeutics' drug candidates; the risk that the preliminary or interim results of its preclinical or clinical trials may not be predictive of future or final results in connection with future clinical trials of its product candidates and that interim and early clinical data may change as more patient data become available and are subject to audit and verification procedures; Relay Therapeutics' ability to successfully demonstrate the safety and efficacy of its drug candidates; the timing and outcome of its planned interactions with regulatory authorities; and obtaining, maintaining and protecting its intellectual property. These and other risks and uncertainties are described in greater detail in the section entitled "Risk Factors" in Relay Therapeutics' most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, as well as any subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent Relay Therapeutics' views only as of today and should not be relied upon as representing its views as of any subsequent date. Relay Therapeutics explicitly disclaims any obligation to update any forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward- looking statements.

    Contact:

    Pete Rahmer

    [email protected]

    Media:

    Dan Budwick

    1AB

    973-271-6085

    [email protected]

    Relay Therapeutics, Inc.

    Condensed Consolidated Statements of Operations and Comprehensive Loss

    (In thousands, except share and per share data)

    (Unaudited)

      Three Months Ended

    December 31,
      Twelve Months Ended

    December 31,
     
      2024   2023   2024   2023  
    Revenue:            
    License and other revenue $—   $—   $10,007   $25,546  
    Total revenue  —    —    10,007    25,546  
    Operating expenses:            
    Research and development expenses $68,075   $77,496   $319,089   $330,018  
    Change in fair value of contingent consideration liability  —    (2,066)   (13,206)   (6,422) 
    General and administrative expenses  16,904    16,766    76,592    74,950  
    Total operating expenses  84,979    92,196    382,475    398,546  
    Loss from operations  (84,979)   (92,196)   (372,468)   (373,000) 
    Other income:            
    Interest income  8,974    8,700    34,746    31,045  
    Other income (expense)  1    1    14    (18) 
    Total other income, net  8,975    8,701    34,760    31,027  
    Net loss $(76,004)  $(83,495)  $(337,708)  $(341,973) 
    Net loss per share, basic and diluted $(0.45)  $(0.67)  $(2.36)  $(2.79) 
    Weighted average shares of common stock, basic and diluted  167,337,579    124,752,843    142,867,844    122,576,527  
    Other comprehensive (loss) income:            
    Unrealized holding loss (gain)  (3,500)   3,190    (795)   10,224  
    Total other comprehensive (loss) income  (3,500)   3,190    (795)   10,224  
    Total comprehensive loss $(79,504)  $(80,305)  $(338,503)  $(331,749) 



    Relay Therapeutics, Inc.

    Selected Condensed Consolidated Balance Sheet Data

    (In thousands)

    (Unaudited)

      December 31,

    2024
      December 31,

    2023
     
    Cash, cash equivalents and investments $781,323  $750,086 
    Working capital (1)  758,475   739,834 
    Total assets  871,296   843,980 
    Total liabilities  93,504   91,977 
    Total stockholders' equity  777,792   752,003 
    Restricted cash  2,119   2,707 

     (1) Working capital is defined as current assets less current liabilities.



    Primary Logo

    Get the next $RLAY alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $RLAY

    DatePrice TargetRatingAnalyst
    4/17/2025$4.00Equal Weight
    Wells Fargo
    9/10/2024$20.00Buy
    Goldman
    9/10/2024Outperform → Perform
    Oppenheimer
    9/10/2024$10.60 → $16.00Hold → Buy
    Jefferies
    5/10/2024$15.00Equal Weight → Overweight
    Barclays
    4/20/2023$12.50Underperform → Hold
    Jefferies
    4/19/2023$29.00Outperform → Strong Buy
    Raymond James
    4/13/2023$29.00Outperform
    Raymond James
    More analyst ratings

    $RLAY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Wells Fargo initiated coverage on Relay Therapeutics with a new price target

      Wells Fargo initiated coverage of Relay Therapeutics with a rating of Equal Weight and set a new price target of $4.00

      4/17/25 8:33:19 AM ET
      $RLAY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Goldman resumed coverage on Relay Therapeutics with a new price target

      Goldman resumed coverage of Relay Therapeutics with a rating of Buy and set a new price target of $20.00

      9/10/24 7:59:04 AM ET
      $RLAY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Relay Therapeutics downgraded by Oppenheimer

      Oppenheimer downgraded Relay Therapeutics from Outperform to Perform

      9/10/24 7:58:33 AM ET
      $RLAY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $RLAY
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Relay Therapeutics Inc.

      SCHEDULE 13G/A - Relay Therapeutics, Inc. (0001812364) (Subject)

      7/29/25 2:22:24 PM ET
      $RLAY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 8-K filed by Relay Therapeutics Inc.

      8-K - Relay Therapeutics, Inc. (0001812364) (Filer)

      6/11/25 4:12:42 PM ET
      $RLAY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 8-K filed by Relay Therapeutics Inc.

      8-K - Relay Therapeutics, Inc. (0001812364) (Filer)

      6/6/25 5:00:55 PM ET
      $RLAY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $RLAY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • With Public Funding Under Pressure, Biotech Innovators Are Picking Up the Slack in Oncology

      USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 20, 2025 /PRNewswire/ -- USA News Group News Commentary – The costs of cancer drugs is skyrocketing, according to a recent report from Bloomberg. Analysts at Nova One Advisor estimate that the global oncology drugs market will grow at a 7.4% CAGR through to US$366.24 billion by 2034. Help doesn't appear to be coming from the public sector, as reports state that the current US administration could drastically reduce funding of the National Cancer Institute (NCI) by nearly 40%, the market is looking towards the private sector to pick up the slack and continue to make advancements in cancer treatment.

      6/20/25 9:21:00 AM ET
      $GRAL
      $IMRX
      $INTS
      $ONCY
      Medical Specialities
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors

      CAMBRIDGE, Mass., June 11, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced the appointment of Claire Mazumdar, Ph.D., to the Company's Board of Directors, effective June 9, 2025. "It is a privilege to welcome Claire to our Board, where she will draw from her strategic and operational experience in clinical-stage oncology to offer guidance as we prepare to initiate our Phase 3 ReDiscover-2 trial in breast cancer soon," said Sanjiv Patel, M.D., President and Chief Executive Officer of Relay Therapeutics.

      6/11/25 4:05:00 PM ET
      $BCAX
      $RLAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Relay Therapeutics Announces Updated Data for RLY-2608 + Fulvestrant Further Demonstrating Clinically Meaningful Progression Free Survival at ASCO 2025

      Updated interim data remain consistent, showing 10.3-month median PFS overall and 11.0-month median PFS in 2L patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer Data continue to support planned initiation of pivotal study in mid-2025 Next-generation triplet combinations with atirmociclib (CDK4-selective) & ribociclib ongoing CAMBRIDGE, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced updated interim clinical data for RLY-2608, the first known investigational allosteric, pan-

      6/2/25 7:00:13 AM ET
      $RLAY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $RLAY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Catinazzo Thomas sold $74,000 worth of shares (20,081 units at $3.69), decreasing direct ownership by 6% to 335,295 units (SEC Form 4)

      4 - Relay Therapeutics, Inc. (0001812364) (Issuer)

      7/30/25 4:54:19 PM ET
      $RLAY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Officer Rahmer Peter sold $62,947 worth of shares (17,083 units at $3.68), decreasing direct ownership by 4% to 377,998 units (SEC Form 4)

      4 - Relay Therapeutics, Inc. (0001812364) (Issuer)

      7/30/25 4:54:35 PM ET
      $RLAY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • President, R&D Bergstrom Donald A sold $113,478 worth of shares (30,770 units at $3.69), decreasing direct ownership by 5% to 552,720 units (SEC Form 4)

      4 - Relay Therapeutics, Inc. (0001812364) (Issuer)

      7/30/25 4:54:05 PM ET
      $RLAY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $RLAY
    Leadership Updates

    Live Leadership Updates

    See more
    • Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors

      CAMBRIDGE, Mass., June 11, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced the appointment of Claire Mazumdar, Ph.D., to the Company's Board of Directors, effective June 9, 2025. "It is a privilege to welcome Claire to our Board, where she will draw from her strategic and operational experience in clinical-stage oncology to offer guidance as we prepare to initiate our Phase 3 ReDiscover-2 trial in breast cancer soon," said Sanjiv Patel, M.D., President and Chief Executive Officer of Relay Therapeutics.

      6/11/25 4:05:00 PM ET
      $BCAX
      $RLAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Section 32 Raises $740 Million Venture Fund

      SAN DIEGO, Nov. 4, 2021 /PRNewswire/ -- Section 32 announced today the closing of its fourth fund, raising approximately $740 million from returning and new investors. Investors in Fund 4 include leading philanthropic and non-profit organizations, educational endowments and foundations, and leaders from the technology and healthcare sectors. Section 32 Fund 4 will support companies across all stages that are pioneering innovations at the forefront of technology and healthcare. With the closing of its oversubscribed Fund 4 and to support its continued growth, Section 32 also announced the appointment of Nina Labatt to the role of Chief Operating Officer and Chief Financial Officer.

      11/4/21 8:14:00 AM ET
      $COIN
      $CRWD
      $EXAS
      $RLAY
      Finance: Consumer Services
      Finance
      Computer Software: Prepackaged Software
      Technology
    • Octant Bio Appoints Industry Veteran Mark Murcko as Strategic Advisor and Board Member

      Murcko brings over 30 years of chemistry development in biotech experience to the synthetic biology startup Today, Octant, a therapeutics company integrating novel high-throughput experimental technologies with computation to solve complex challenges in drug discovery, announced the appointment of Mark Murcko as Strategic Advisor and Board Member. Murcko brings over three decades of industry experience, having been at the center of many transformational biotech efforts, most recently as founding CSO and Board Member of Dewpoint Therapeutics. Murcko is working closely with the company to scale Octant to its next phase of growth and further develop its chemistry platform. This press release

      10/14/21 8:00:00 AM ET
      $RLAY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $RLAY
    Financials

    Live finance-specific insights

    See more
    • Relay Therapeutics Announces Updated Interim Data for RLY-2608 + Fulvestrant Demonstrating Continued Maturation of Clinically Meaningful Progression Free Survival

      New interim data show 11.4-month median PFS in 2L patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer at RP2D 39% confirmed ORR across all patients & 67% in patients with kinase mutations at RP2D Data support planned initiation of 2L pivotal study in 2025 Next-generation triplet combination with atirmociclib (CDK4-selective) initiated & ribociclib triplet combination ongoing Relay Therapeutics to host a conference call today, December 11, at 7am ET (6am CT) SAN ANTONIO, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and expe

      12/11/24 6:00:00 AM ET
      $RLAY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Relay Therapeutics to Present Updated Clinical Data on RLY-2608 in HR+/HER2- Breast Cancer at 2024 San Antonio Breast Cancer Symposium

      CAMBRIDGE, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that updated clinical data for RLY-2608 600mg BID + fulvestrant in patients with PI3Kα-mutated, HR+, HER2- locally advanced or metastatic breast cancer will be presented at the upcoming San Antonio Breast Cancer Symposium, taking place December 10-13, 2024. Details of the RLY-2608 + fulvestrant poster presentation are as follows:Abstract Title: PS7-01: Efficacy of RLY-2608, a mutant-selective PI3Kα inhibitor in patients with PIK3C

      12/9/24 4:05:30 PM ET
      $RLAY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Relay Therapeutics Announces Positive Interim Data for RLY-2608 Demonstrating Clinically Meaningful Progression Free Survival

      9.2-month median PFS in heavily pre-treated patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer at RP2D 33% ORR across all patients & 53% ORR in patients with kinase mutations at RP2D Favorable overall tolerability profile; at RP2D, only 2 patients discontinued treatment due to adverse events & only 1 patient experienced Grade 3 hyperglycemia Data support planned initiation of 2L pivotal study in 2025 Triplet combination with ribociclib expected to move into dose expansion in 1H 2025 & triplet combination with atirmociclib (CDK4) remains on track to start before year-end Relay Therapeutics to host a conference call today, September 9, at 8:00 a.m. ET CAMBRIDGE,

      9/9/24 6:55:20 AM ET
      $RLAY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $RLAY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Relay Therapeutics Inc.

      SC 13G/A - Relay Therapeutics, Inc. (0001812364) (Subject)

      11/14/24 1:22:38 PM ET
      $RLAY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Relay Therapeutics Inc. (Amendment)

      SC 13G/A - Relay Therapeutics, Inc. (0001812364) (Subject)

      2/14/24 4:20:24 PM ET
      $RLAY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Relay Therapeutics Inc.

      SC 13G - Relay Therapeutics, Inc. (0001812364) (Subject)

      2/14/24 10:03:03 AM ET
      $RLAY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care